Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic ITI in CRIM-Negative Infantile Pompe Disease
NCT00701129Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2009
- Primary completion
- Mar 2013
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoints: Change From Baseline in Number of Patients With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at Week 79, Number of Patients With Recombinant Human Acid Alfa-glucosidase (rhGAA) Inhibitory Antibody at Week 79 and 6 more. Started Oct 2009; status: completed.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT00701129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701129.